Abstract
The Prospective Randomized Milrinone Survival Evaluation (PROMISE) was conducted to clarify discordant findings in previous experimental and clinical studies with milrinone, a cyclic AMP-enhancing positive inotropic agent. Earlier studies had shown positive effects of milrinone on cardiac function and exercise performance in patients with chronic heart failure. To determine the effect of milrinone on mortality, patients with severe chronic heart failure who remained symptomatic despite conventional therapy were randomized to receive either active drug or a matching placebo. The trial was terminated after 20 months, before its scheduled completion, based on an observed adverse effect of milrinone on survival. This paper describes the experience of the Data Monitoring and Safety Monitoring Board (DSMB) in dealing with an emerging negative trend in survival when there were other known beneficial effects of the drug.
Access provided by Autonomous University of Puebla. Download to read the full chapter text
Chapter PDF
Similar content being viewed by others
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
References
Packer M. 1988. Vasodilator and inotropic drugs for chronic heart failure: distinguishing hype from hope. Am J Cardiol 12:1299–1317.
Feldman MD, Copelas L, Gwanthmey JK, et al. 1987. Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75:331–339.
Wilmshurst PT, Walker Jm, Fry CH, et al. 1984. Inotropic and vasodilator effects of amrinone on isolated human tissue. Cardiovasc Res 18:302–309.
Jain P, Brown EJ Jr, Langenback EG, et al. 1991. Effects of milrinone on left ventricular remodeling after acute myocardial infarction. Circulation 84:796–804.
Sweet CS, Ludden CT, Stabilito II, Emmert SE, Heyse JF. 1988. Beneficial effects of milrinone and enalapril on long-term survival of rats with healed myocardial infarction. Eur J Pharmacol 147:29–37.
Packer M, Leier CV. 1987. Survival in congestive heart failure during treatment with drugs with positive inotropic actions. Circulation 75:Suppl IV:IV-55–IV-63.
DiBianco R, Shabetai R, Kostuk W, Moran J, Schlant RC, Wright R. 1989. A comparison of oral milrinone, digoxin, and their combination in the treatment of patients wiht chronic heart failure. N Engl J Med 320:677–683.
Baim DS, McDowell AV, Cherniles J, et al. 1983. Evaluation of a new bipyridine inotropic agent—milrinone—in patients with severe congestive heart failure. N Engl J Med 309:748–756.
Simonton CA, Chatterjee K, Cody RJ, et al. 1985. Milrinone in congestive heart failure: acute and chronic hemodynamic and clinical evaluation. J Am Coll Cardiol 6:453–459.
Chesebro JH, Browne KF, Fenster PE, Garland WT, Konstam MA. 1988. The hemodynamic effects of chronic oral milrinone therapy: a multicenter controlled trial. J Am Coll Cardiol 11:144A. abstract
Packer M. 1989. Effect of phosphodiesterase inhibitors on the survival of patients with chronic congestive heart failure. Am J Cardiol 63:41A–45A.
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. 1991. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325:1468–1475.
Fisher MM, Roecker EB, DeMets D. 2001. The role of an independent statistical analysis center in the industry-modified National Institutes of Health model. Drug Information Journal 35:115–129.
Lan KKG, DeMets DL. 1983. Discrete sequential boundaries for clinical trials. Biometrika 70:659–663.
O’Brien PC, Fleming TR. 1979. A multiple testing procedure for clinical trials. Biometrics 35:549–556.
DeMets DL, Pocock S, Julian DG: 1999. The agonising negative trend in monitoring clinical trials. Lancet 354:1983–1988.
US Food and Drug Administration (2001) Draft Guidance for Clinical Trial sponsors on the establishment and operation of Clinical Trial Data Monitoring Committees. Rockville, MD: FDA. http://www.fda.gov/cber/gdlns/clindatmon.htm
Ellenberg S, Fleming T, DeMets D. 2002. Data Monitoring Committees in Clinical Trials: A Practical Perspective. John Wiley & Sons, Ltd., West Sussex, England.
Canner PL. 1983. Monitoring of the data for evidence of adverse or beneficial treatment effects. Control Clin Trials 4:467–483.
Friedman LM, Furberg CD, DeMets DL. 1998. Fundamentals of Clinical Trials. Third Edition, Springer-Verlag, New York.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Anderson, S., Cody, R., Packer, M., Schwarz, R. (2006). Data Monitoring in the Prospective Randomized Milrinone Survival Evaluation: Dealing With an Agonizing Trend. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_19
Download citation
DOI: https://doi.org/10.1007/0-387-30107-0_19
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-20330-0
Online ISBN: 978-0-387-30107-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)